Xencor Inc (XNCR.OQ)
XNCR.OQ on NASDAQ Stock Exchange Global Market
42.89USD
21 Sep 2018
42.89USD
21 Sep 2018
Change (% chg)
$-2.50 (-5.51%)
$-2.50 (-5.51%)
Prev Close
$45.39
$45.39
Open
$45.24
$45.24
Day's High
$45.82
$45.82
Day's Low
$42.70
$42.70
Volume
487,008
487,008
Avg. Vol
121,629
121,629
52-wk High
$48.31
$48.31
52-wk Low
$19.00
$19.00
About
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials... (more)
Overall
| Beta: | 1.57 |
| Market Cap(Mil.): | $2,394.38 |
| Shares Outstanding(Mil.): | 55.83 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| XNCR.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 108.45 | 32.71 |
| EPS (TTM): | -1.16 | -- | -- |
| ROI: | -14.21 | 1.54 | 12.72 |
| ROE: | -14.36 | 0.30 | 14.84 |
BRIEF-Xencor Reports Q1 Loss Per Share $0.62
* Q1 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S
Competitors
| Price | Chg | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $44.06 | +0.31 |
| Novartis AG (NOVN.S) | CHF81.88 | -0.06 |
| Roche Holding Ltd. (ROG.S) | CHF235.15 | +0.10 |
| Roche Holding Ltd. (RO.S) | CHF235.40 | -1.20 |
| AstraZeneca plc (AZN.L) | 5,670.00 | +98.00 |
| GlaxoSmithKline plc (GSK.L) | 1,531.40 | +45.60 |
| AbbVie Inc (ABBV.N) | $92.26 | -0.42 |
| Bristol-Myers Squibb Co (BMY.N) | $62.25 | +0.50 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $1,034.45 | -- |
| Amgen, Inc. (AMGN.OQ) | $205.10 | 0.00 |
Estimates